These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37214654)

  • 1. Phage Therapy Administration Route, Regimen, and Need for Supplementary Antibiotics in Patients with Chronic Suppurative Lung Disease.
    Williams J; Severin J; Temperton B; Mitchelmore PJ
    Phage (New Rochelle); 2023 Mar; 4(1):4-10. PubMed ID: 37214654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong T; Salabarria AC; Roach DR
    Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phage therapy for respiratory infections.
    Chang RYK; Wallin M; Lin Y; Leung SSY; Wang H; Morales S; Chan HK
    Adv Drug Deliv Rev; 2018 Aug; 133():76-86. PubMed ID: 30096336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phage steering of antibiotic-resistance evolution in the bacterial pathogen,
    Gurney J; Pradier L; Griffin JS; Gougat-Barbera C; Chan BK; Turner PE; Kaltz O; Hochberg ME
    Evol Med Public Health; 2020; 2020(1):148-157. PubMed ID: 34254028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking the phage trends: A comprehensive review of applications in therapy and food production.
    Jaglan AB; Anand T; Verma R; Vashisth M; Virmani N; Bera BC; Vaid RK; Tripathi BN
    Front Microbiol; 2022; 13():993990. PubMed ID: 36504807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics.
    Usman SS; Uba AI; Christina E
    Mol Biol Rep; 2023 Aug; 50(8):7055-7067. PubMed ID: 37392288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
    Ryan EM; Gorman SP; Donnelly RF; Gilmore BF
    J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacteriophages to Treat Tuberculosis: Dream or Delusion?
    Diacon AH; Guerrero-Bustamante CA; Rosenkranz B; Rubio Pomar FJ; Vanker N; Hatfull GF
    Respiration; 2022; 101(1):1-15. PubMed ID: 34814151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and Characterization of Three Pseudomonas aeruginosa Viruses with Therapeutic Potential.
    Wang X; Tang J; Dang W; Xie Z; Zhang F; Hao X; Sun S; Liu X; Luo Y; Li M; Gu Y; Wang Y; Chen Q; Shen X; Xu L
    Microbiol Spectr; 2023 Jun; 11(3):e0463622. PubMed ID: 37125933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage Therapy in the Era of Multidrug Resistance in Bacteria: A Systematic Review.
    Aranaga C; Pantoja LD; Martínez EA; Falco A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against
    Rossitto M; Fiscarelli EV; Rosati P
    Front Microbiol; 2018; 9():775. PubMed ID: 29780361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled Bacteriophage Therapy for Multi-Drug Resistant
    Winzig F; Gandhi S; Lee A; Würstle S; Stanley GL; Capuano I; Neuringer I; Koff JL; Turner PE; Chan BK
    Yale J Biol Med; 2022 Dec; 95(4):413-427. PubMed ID: 36568830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes.
    Green SI; Clark JR; Santos HH; Weesner KE; Salazar KC; Aslam S; Campbell JW; Doernberg SB; Blodget E; Morris MI; Suh GA; Obeid K; Silveira FP; Filippov AA; Whiteson KL; Trautner BW; Terwilliger AL; Maresso A
    Clin Infect Dis; 2023 Oct; 77(8):1079-1091. PubMed ID: 37279523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temperate Bacteriophages from Chronic Pseudomonas aeruginosa Lung Infections Show Disease-Specific Changes in Host Range and Modulate Antimicrobial Susceptibility.
    Tariq MA; Everest FLC; Cowley LA; Wright R; Holt GS; Ingram H; Duignan LAM; Nelson A; Lanyon CV; Perry A; Perry JD; Bourke S; Brockhurst MA; Bridge SH; De Soyza A; Smith DL
    mSystems; 2019 Jun; 4(4):. PubMed ID: 31164451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases.
    Cesta N; Di Luca M; Corbellino M; Tavio M; Galli M; Andreoni M
    Infez Med; 2020 Sep; 28(3):322-331. PubMed ID: 32920567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.
    Dedrick RM; Smith BE; Cristinziano M; Freeman KG; Jacobs-Sera D; Belessis Y; Whitney Brown A; Cohen KA; Davidson RM; van Duin D; Gainey A; Garcia CB; Robert George CR; Haidar G; Ip W; Iredell J; Khatami A; Little JS; Malmivaara K; McMullan BJ; Michalik DE; Moscatelli A; Nick JA; Tupayachi Ortiz MG; Polenakovik HM; Robinson PD; Skurnik M; Solomon DA; Soothill J; Spencer H; Wark P; Worth A; Schooley RT; Benson CA; Hatfull GF
    Clin Infect Dis; 2023 Jan; 76(1):103-112. PubMed ID: 35676823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric chronic suppurative lung disease: clinical characteristics and outcomes.
    Goyal V; Grimwood K; Marchant JM; Masters IB; Chang AB
    Eur J Pediatr; 2016 Aug; 175(8):1077-84. PubMed ID: 27287408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alginate microbeads and hydrogels delivering meropenem and bacteriophages to treat Pseudomonas aeruginosa fracture-related infections.
    Chen B; Benavente LP; Chittò M; Wychowaniec JK; Post V; D'Este M; Constant C; Zeiter S; Feng W; Moreno MG; Trampuz A; Wagemans J; Onsea J; Richards RG; Lavigne R; Moriarty TF; Metsemakers WJ
    J Control Release; 2023 Dec; 364():159-173. PubMed ID: 37866403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection.
    Ferry T; Kolenda C; Briot T; Souche A; Lustig S; Josse J; Batailler C; Pirot F; Medina M; Leboucher G; Laurent F; On Behalf Of The Lyon Bji Study Group ; On Behalf Of The PHAGEinLYON Study Group
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.